Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Clinical Nuclear Medicine|September 1, 1995
Moyamoya disease in twinsY Duman, A Dirlik, Z Burak, et al.Clinical Nuclear Medicine|August 31, 1999
False-negative scintigraphy with Tc-99m sestamibi in stage IV neuroblastomaZ Ozcan, G Erenel, S Aksoylar, et al.Nuclear Medicine Communications|November 26, 1999
The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: comparison with 131I-MIBG and 99Tcm-MDP scintigraphyZ Burak, D A Yüksel, N Cetingül, et al.Nuclear Medicine Communications|September 1, 1996
Is 201Tl a reliable agent in tumour imaging?Z Ozcan, Z Burak, C Ozcan, et al.Nuclear Medicine Communications|June 14, 2001
Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumoursZ Ozcan, Z Burak, R Erinç, et al.Nuclear Medicine Communications|April 21, 1998
The role of 99Tcm-tetrofosmin myocardial perfusion scintigraphy in the assessment of patients with previous myocardial infarction: a comparative study with 201TlZ Burak, H Akin, S Buket, et al.Nuclear Medicine Communications|February 9, 1999
Assessment of chemotherapy-induced changes in bone sarcomas: clinical experience with 99Tcm-MDP three-phase dynamic bone scintigraphyZ Ozcan, Z Burak, K Kumanlioğlu, et al.European Journal of Nuclear Medicine|October 5, 2001
The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy responseZ Burak, O Ersoy, J L Moretti, et al.Nuclear Medicine Communications|June 1, 1993
The value and limitations of 201Tl scintigraphy in the evaluation of lung lesions and post-therapy follow-up of primary lung carcinomaY Duman, Z Burak, S Erdem, et al.Nuclear Medicine Communications|May 1, 1996
Accumulation of 99Tcm-polyclonal immunoglobulin in different stages of infection: an experimental studyZ Burak, Z B Ozcan, C Ozcan, et al.Pageof 2